Agoracom Blog Home

Archive for the ‘Empower Clinics Inc.’ Category

« Older Entries
Newer Entries »

Empower Clinics $CBDT.ca – #Marijuana Survey Shows #Boomers Embracing #Cannabis & #CBD According to Aging Expert, Lisa Cini $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:15 PM on Monday, March 16th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

Marijuana Survey Shows Boomers Embracing Cannabis & CBD According to Aging Expert, Lisa Cini

COLUMBUS, Ohio -With 9 in 10 Americans favoring legalization of Marijuana for recreation or medicinal purposes and New York weeks away from a decision, aging expert Lisa Cini shares details of marijuana and cannabidiol (CBD) usage among the 11,000+ boomers who responded to her marijuana survey and answered a variety of questions on marijuana consumption, opinion, and usage.

“It’s time to mainstream senior-friendly tools for using marijuana, and consider implications for designing seniors’ living spaces, or help those marijuana-using seniors living in multi-generational homes to partake in designated ways and areas as not to offend family members who don’t use, including children and grandchildren.”Tweet this

“I’m not surprised that 83% of the respondents are using some form of cannabis for recreational and medical reasons. 66% partake daily and believe that marijuana and/or CBD use is an important component of their lives,” says Lisa Cini, senior living expert and author of BOOM: The Baby Boomers Guide to Leveraging Technology, so that you can Preserve Your Independent Lifestyle & Thrive. “Don’t forget that much of the boomer generation grew up smoking weed. Some never stopped, resumed in retirement, or when they were no longer raising children. Because the aging process is unforgiving as it relates to pain, seniors are finding relief from achy bones and joints, arthritis, sleeplessness, and many other ailments, proving that there’s a great deal more to marijuana than just getting high, especially for those battling health and comfort challenges.”

Seniors are using weed in any number of ways, from smoking to baking and preparing full meals with cannabutter for many perceived health benefits including relief from insomnia, anxiety, chronic pain, depression, muscle tension, arthritis, and migraines in addition to getting high.

For those who desire CBD without THC, popular brands like vitafusion™ now offer gummy vitamins with full spectrum hemp extract and natural phytocannabinoids (225mg & 10mg CBD per gummy), Blissful Sleep with 5mg Melatonin (300mg with 10mg CBD per gummy) to induce sleep, and Chillaxed Mood with natural phytocannabinoids & 10mg L-Theanine (300 mg & 10mg CBD per gummy) to promote calm mental alertness, in contrast to the restless energy sometimes produced by caffeine. CBD creams and other skin care products are touted for anti-aging and appeal to boomers. CBD Anti-Aging Cream with Apple Stem Cells, was voted #1 Best Anti-Aging CBD Skin Cream in 2019 and for those with sensitive skin, Abinoid Botanicals Face Serum – Blue Chamomile & Hemp was voted #2 best hemp cream.

“Marijuana and CBD use is a reality that can no longer be ignored, as it’s very much a part of the daily lives of so many,” adds Cini. “It’s time to mainstream senior-friendly tools for using marijuana, and consider implications for designing seniors’ living spaces, or help those marijuana-using seniors living in multi-generational homes to partake in designated ways and areas as not to offend family members who don’t use, including children and grandchildren.”

Lisa Cini is an award-winning senior living designer, President / CEO, Mosaic Design Studio and author of BOOM: The Baby Boomers Guide to Leveraging Technology, so that you can Preserve Your Independent Lifestyle & Thrive, The Future is Here: Senior Living Re-imagined, and Hive, which describes her family’s four generations living under the same roof in her own home. Go to Lisamcini.com to sign up for her blog. If you want to find the best tech products that help seniors Embrace Aging and Live Independently, visit BestLivingTech.com.

Source: https://www.businesswire.com/news/home/20200309005150/en/Marijuana-Survey-Shows-Boomers-Embracing-Cannabis-CBD

Tags: , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – #Marijuana Survey Shows #Boomers Embracing #Cannabis & #CBD According to Aging Expert, Lisa Cini $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca – #Cannabis Won’t Cure #Coronavirus, but It Can Help Ease Certain Flu Symptoms $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:00 PM on Friday, March 13th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

Cannabis Won’t Cure Coronavirus, but It Can Help Ease Certain Flu Symptoms

By Brianna Wheeler |

During a normal flu season, frequent weed smokers know the drill.

Pay closer attention to everyone’s cough patterns during a smoke sesh. Stop accepting mouth-wet blunts from strangers. And if you think you’re coming down with something, wave a lighter under the mouthpiece before passing the pipe.

This year, obviously, things are a bit more serious. We’re dealing with multiple citywide quarantines, global economic disruption, and a pandemic being compared to the damn Spanish flu. It’s enough to make self-respecting cannabis enthusiasts re-evaluate their medicine cabinet and diversify their stash box.

Obviously, there’s no dependable research on CBD’s or THC’s effect on COVID-19. But we do know a few things about cannabis and general wellness. Down the rabbit hole of alternative cannabinoids and non-psychoactive cannabis, there is a wealth of potential medicinal benefits both preventative and curative.

At least when it comes to the regular flu, CBD has been found to help support immune systems, ease symptoms, and replace over-the-counter pain relievers, sleep aids, and medicated salves currently taking up space in our medicine cabinet. But not just any CBD will do, and CBD alone won’t do it all.

Obviously, the best course of action right now is to keep vigorously washing your hands, mind your coughs, avoid large crowds, and be a bit more stingy with your pipes and joints. But if you find yourself slipping under the weather, for whatever reason, here are a few things to know about how cannabis might help ease symptoms.

CBD for Immune System Support

Tons more research is required to accurately map the relationship between the immune and endocannabinoid systems, but it’s well established that CBD helps reduce self-harming autoimmune and inflammatory responses. “CBD has been found to act as an immune system modulator,” says Anna Symonds, director of East Fork Cultivars’ CBD Certified program. “This means that it’s like a thermostat—it can turn the level of activity down or up, depending on the body’s needs.”

Source: https://www.wweek.com/potlander/2020/03/10/cannabis-wont-cure-coronavirus-but-it-can-help-ease-certain-flu-symptoms/

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – #Cannabis Won’t Cure #Coronavirus, but It Can Help Ease Certain Flu Symptoms $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca Announces Advancement of Joint Venture with Heritage Cannabis in the United States $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:24 AM on Thursday, March 5th, 2020
  • Announced the advancement of its previously announced Joint Venture Partnership with Heritage Cannabis Holdings Corp. (CSE: CANN), based in Sandy, Oregon, USA.
  • Now advancing the JV with the order and installation of extraction and post-production equipment units at Empower’s existing licenced hemp processing facility in Sandy, Oregon,
  • Will immediately begin performing hemp-based product manufacturing for proprietary formulations, tolling services, and third-party white labelling services for other distributors throughout the United States

VANCOUVER, BC / March 5, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTC:EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce the advancement of its previously announced Joint Venture Partnership (“JV”) with Heritage Cannabis Holdings Corp. (CSE: CANN) (“Heritage”), based in Sandy, Oregon, USA.

In September 2019, Empower announced it had entered into a Letter of Intent (“LOI”) to form a 50/50 ownership JV with Heritage for the extraction of hemp for CBD oil production, and formulated CBD products. The JV is equally funded by both parties and since formation CDN$250,000 has been provided to the JV.

Heritage and Empower are now advancing the JV with the order and installation of extraction and post-production equipment units at Empower’s existing licenced hemp processing facility in Sandy, Oregon, in order to immediately begin performing hemp-based product manufacturing for proprietary formulations, tolling services, and third-party white labelling services for other distributors throughout the United States.

The proprietary branded products will be distributed through Empower’s corporately owned physician staffed health clinics in Oregon and Arizona, online at www.sunvalleyhealth.com and in upcoming new franchise locations, which currently have access to over 165,000 patients.

Additionally, related downstream equipment is now being installed including gel cap processing, tincture bottle and vape cartridge filling, as well as labelling, packaging, storage and shipping services, to offer full-service end-to-end products to third parties.

Heritage is providing training and supervision related to the proprietary methods of extraction and oil production that is already being successfully produced in Canada by Heritage.

“Having the backing of an experienced partner with the financial strength of Heritage Cannabis is proving to be so beneficial for the development of our first extraction facility”, said Steven McAuley, Chief Executive Officer of Empower. “Together, we have already identified numerous opportunities to bring new orders to the JV facility, ensuring we leverage the capacity we are building.”

“We are very pleased to be advancing our U.S. strategy through this mutually beneficial partnership with Empower, which provides Heritage ease of access to the world’s largest cannabis market”, stated Clint Sharples, Chief Executive Officer of Heritage. “The installation of extraction units is the next phase of the JV and another step toward successfully furthering our growth strategies.”

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

About Heritage Cannabis Holdings Corp.

The Company is focused on becoming a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and a Medical Services Division which is focused on cannabis based medical solutions. Heritage as the parent company, is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Advancement of Joint Venture with Heritage Cannabis in the United States $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca Announces Significant Patient Growth in February 2020 with Visits Increasing by 800% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:02 AM on Wednesday, March 4th, 2020
  • Patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019
  • Total patient visits of 1,817 in February 2020 compared to 227 in February 2019

VANCOUVER, BC / March 4, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company, is pleased to announce that patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019, with total patient visits of 1,817 in February 2020 compared to 227 in February 2019.

“Patient volumes have remained strong to start the year in all clinics, continuing on our push for a record first quarter.” said Dustin Klein, SVP Business Development and Director of Empower. “Operational excellence each day, combined with exemplary care for the patient, sets us apart in the markets we serve.”

The Company also has received numerous inquiries with both positive and supportive sentiment, after the recent announcement of the Company’s intention to create a psilocybin and psychedelics division.

“Getting positive reinforcement from researchers, physicians, advocates and practitioners about our intention to enter this developing field of study, gives me confidence that we have made the correct decision to leverage our corporate assets for psilocybin and psychedelics research and development.” said Steven McAuley, Chairman & CEO of Empower.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Significant Patient Growth in February 2020 with Visits Increasing by 800% $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca – CBD consumption to rise across the treatment of neurological conditions $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 1:53 PM on Thursday, February 27th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD consumption to rise across the treatment of neurological conditions

Research shows that CBD consumption for the treatment of neurological conditions is set to rise.

  • With an exponential rise in the availability of CBD products and public opinion towards it becoming more positive over the past decade, the consumption of the ingredient has exploded.
  • Global Market Insights, Inc., forecasts that global cannabidiol market size will be worth more than $89bn by 2026.

By: Health Europa

However, the industry will need to overcome the complex regulatory landscape as well as quality and supply challenges in the near future.

Over the past few years, cannabidiol, or CBD, has caught the public’s imagination as an ingredient presenting a range of health benefits when infused in various consumables. More and more individuals worldwide are now vouching for its effectiveness in terms of alleviating certain chronic illnesses and treating several health conditions.

CBD has conquered industry after industry, from pharmaceuticals to personal care and cosmetics, food and beverages, and nutraceuticals.

Cannabidiol is the legal and non-psychoactive counterpart of tetrahydro cannabidiol (THC), the chemical compound responsible for cannabis’s psychological effects. CBD is the second most-commonly used active ingredients of cannabis. The cannabinoid is derived directly from the hemp plant, a cousin of the cannabis plant, and forms an essential component of medical cannabis.

CBD regulatory landscape in Europe

Factors such as population growth, nationalised healthcare, GDP, and cultural historic use of CBD in many European countries make the continent an attractive market for global producers of both medical and retail cannabis-based products. Hemp cultivation in the region has witnessed a massive upsurge in recent years; the European Union (EU) constitutes more than 25% of the global hemp production.

In July last year Epidiolex CBD oil received a positive recommendation for marketing approval from the European Medicines Agency (EMA) for the treatment of seizures. EMA’s Human Medicines Committee (CHMP) approved the oral solution for use with clobazam for the treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients aged two or more.

The European Commission granted marketing approval to Epidyolex, the trade name for Epidiolex in Europe, in September 2019. Epidiolex is the only federally-approved CBD product in the U.S.

Additionally, the use of CBD in cosmetics is harmonised within the European Cosmetic Regulation 1223/2009. The regulation prohibits the use of cannabis and its derivatives in cosmetic products. Essentially, EU prohibits the use of CBD derived naturally from cannabis plants. However, the use of hemp-derived or synthetically-produced cannabidiol is approved.

Europe CBD market is poised to witness monumental growth in the forthcoming years on account of surging consumer demand for safe-strength CBD products that are easily available in their normal retail environments and cultivated, extracted, processed and labelled as per the European standards.

Growing burden of neurological diseases in Europe

Europe has witnessed a growing occurrence of various neurological conditions in recent years. These include epilepsy, migraine, stress, anxiety, and numerous sleeping disorders. An expanding geriatric population base indicates rising incidences of these conditions. Citing data from the European Brain Council, more than 220 million people in Europe suffer from at least one neurological condition, which is more than the populations of France, Germany, and the Great Britain combined.

Described below are some of the most prevalent neurological conditions in Europe and the effectiveness of CBD in their treatment.

  • Stress and anxiety – Nearly 25% of the European population suffers from stress, anxiety or depression each year. The effectiveness of CBD products as anti-anxiety nutraceuticals is backed with plenty of research, however there is still a long way to go. Several clinical trials have provided considerable evidence of cannabidiol’s usefulness for the treatment of generalised anxiety disorder (GAD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), social anxiety disorder, and panic disorder;
  • Migraine – Migraine currently affects more than 11% of the global population. The social societal burden of migraine in Europe is an approximately €27bn per year. While pain medications are known to help temporarily alleviate the symptoms of migraine, they can have several side-effects. Research concerning the use of cannabidiol for migraine is limited however a number of laboratory studies suggest that CBD oil may help reduce all types of acute and chronic pain, including migraine; and
  • Seizures – In Europe, close to six. million people suffer from epilepsy, while 15 million people will have at least one seizure at some point during their lifetime. Numerous research studies over the years have demonstrated the benefits and effectiveness of hemp-derived CBD products in patients with epilepsy who have not responded to traditional treatment.

Surging popularity of cannabidiol among boomers along with ongoing research and development into its potential health benefits will augment CBD market forecast. More and more boomers are adding CBD to their health regimes to help reduce stress and anxiety, get better sleep, and alleviate chronic pain. Increasing awareness towards the safety and efficacy of cannabidiol products will drive future CBD industry trends.

Source: https://www.healtheuropa.eu/cbd-consumption-to-rise-across-the-treatment-of-neurological-conditions/98105/

Tags: , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – CBD consumption to rise across the treatment of neurological conditions $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:05 PM on Wednesday, February 26th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD Sales Predicted to Grow, Market Analysis Finds

  • U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019
  • On pace to increase 18% per year to $33 billion in 2024

By WholeFoods Magazine Staff

Rockville, MD—U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019, and are on pace to increase 18% per year to $33 billion in 2024, according to data published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.

The most common delivery format for cannabis, the flower—smoked as buds or as cigarettes—accounts for nearly 40% of retail sales, according to a press release. Vaporizer cartridges with concentrated THC or CBD compounds takes the second largest share, but it’s falling, as concerns about vaping-related lung illnesses rise. Edibles and topicals are predicted to rise, and to rise quickly, as they stand to benefit the most from legalization of hemp-based CBD; major retailers are already offering CBD-infused food and beverages, as well as CBD-infused cosmetics.

The report analyzes cannabis and cannabis-related retail trends and opportunities in the U.S., with a focus on multi-state cannabis dispensary operators and food and beverage introductions, as well as market trends by state. It also includes a detailed analysis of cannabis-related legal and regulatory trends at the federal and state levels. The report can be purchased here.

Source: https://wholefoodsmagazine.com/suppliers/news-suppliers/cbd-sales-predicted-to-grow-market-analysis-finds/

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:10 AM on Tuesday, February 25th, 2020
  • Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
  • “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.

The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology.

“There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society.” said Steven McAuley, Chairman & CEO of Empower. “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.”

Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

“Over the past seven years, we have assisted over one hundred thousand patients obtain access to alternative health care and medicinal cannabis. The provision of legal access to psilocybin therapies are perfectly in-line with our philosophy of providing a Scientific Approach to Alternative Medicine™“, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Clinical trials have shown that psilocybin therapies provide tremendous help with conditions we see everyday in our clinics. It is our responsibility, to make sure we are providing the most up-to-date alternative therapies to our patients and our community.”

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

The Company also announces it has issued to Haywood Securities Inc., 4,000,000 common shares of the Company (the “Work Fee Shares”) under the financial advisory agreement dated September 25, 2019 (the “Agreement”) based on Haywood Securities Inc. completing the final written SWOT analysis. The shares issued are priced at fair market value of the common shares of the Corporation as at the date of issuance of the Work Fee Shares.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca – #Cannabis Extraction Stocks Best Profit Play for #Marijuana Investors $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:44 PM on Wednesday, February 19th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Cannabis Extraction Stocks Best Profit Play for Marijuana Investors

Cannabis Extraction Stocks on Pace for Massive Growth

  • Cannabis extraction companies are at the center of the hottest trend to hit the legal cannabis industry in years: marijuana derivatives
  • Those include cannabis-infused products like edibles, vapes, concentrates, beverages, tinctures, and topicals.

By John Whitefoot, BA

In the lead-up to the October 2018 legalization of recreational cannabis in Canada, all eyes were on marijuana growers. It made sense. They were the companies that were going to supply the industry with dried flower. And demand for weed was expected to go through the roof.

While 2019 was a tough year for some pot stocks, 2020 is shaping up to be much better. Not all pot stocks are created equal though. One area that looks like it’s poised to outstrip the broader weed stock market is cannabis extraction stocks.

In 2019, global pot sales soared 48% year-over-year to $15.0 billion. In 2020, marijuana sales are expected to climb 38%. By 2024, global weed sales are projected to top $43.0 billion.  (Source: “Global Cannabis Sales Grow 48% to $15 Billion in 2019,” BDS Analytics, January 16, 2020.)

A compound annual growth rate of 23% is pretty hard to dismiss.

Legal marijuana is a young industry that is providing investors with a lot of choices. In addition to the marijuana producers, there are companies that serve or support those producers—with elements such as hydroponics, processing, extraction, financing, set-up, e-commerce, and operating dispensaries.

So far they have mostly been serving the relatively small Canadian market (Canada has a population less than that of California)—one that, as of September 2019, had yet to generate $1.0 billion in annual legal pot sales. (Source: “The Retail Cannabis Market in Canada: A Portrait of the First Year,” Statistics Canada, Statistics Canada, December 11, 2019.)

That number will likely jump considerably once the Canadian marijuana market matures. Investors who do not want to wait for that to happen, however, might want to consider cannabis extraction stocks.

Why? Cannabis extraction companies are at the center of the hottest trend to hit the legal cannabis industry in years: marijuana derivatives. Those include cannabis-infused products like edibles, vapes, concentrates, beverages, tinctures, and topicals.

Cannabis-Infused Products Are Crucial for the Pot Industry

Cannabis-infused products are opening up a whole new revenue stream for the legal marijuana industry. That’s because these items are being introduced to consumers who may have been reluctant to try traditional cannabis products. Some people like the buzz or the medicinal properties but don’t want to inhale smoke.

A few years ago, in the U.S., roughly 75% of the marijuana market was taken up by cannabis flower. Today that number is around 40%. A similar trend has been happening in Canada. (Source: “Why Business Is Booming for Cannabis Extraction Companies Despite the Supply Shortage,” Financial Post, April 19, 2019.)

That is a godsend for marijuana companies looking to juice their top and bottom lines. That’s because cannabis-infused products have higher margins than traditional dried cannabis does.

Providing products that have high demand and a high profit margin is a no-brainer.

Cannabis Extract Industry Will Be Huge

In January 2020, cannabis-infused products legally hit store shelves in Canada for the first time. That came just a year after the Canadian government approved the sale of recreational marijuana in the form of dried flower, oils, and sprays.

The cannabis extraction industry will be massive, because the sales projections for pot-infused products are huge.

According to one study, the total legal marijuana market in Canada will reach $11.0 billion by 2025. Of that, 54% is expected to come from sales of edibles and other cannabis-extract products. (Source: “One-in-five Canadians will consume cannabis in 2025: Ernst & Young,” Yahoo! Finance Canada, March 26, 2019.)

And that’s just for Canada; the global market for cannabis derivatives is expected to nearly double over the next five or six years to $194.0 billion. (Source: “Canada’s consumer market for edibles estimated to reach at least $1.6 billion annually: Deloitte,” The GrowthOp, June 3, 2019.)

Now, many cannabis companies do not have in-house extraction facilities. To make marijuana-infused products, they need to outsource the work. That’s where cannabis extraction companies come into play.

Instead of growing marijuana, they take hemp and cannabis biomass and process it for the resins, concentrates, distillates, and targeted cannabinoids.

Admittedly, some of the bigger licensed marijuana growers in Canada already have—or are constructing—their own extraction facilities, but it won’t be enough to meet the future demand for cannabis oils.

In fact, some cannabis growers have signed multi-year, renewable extraction agreements with the bigger cannabis extraction companies in Canada.

Analyst Take

Cannabis extraction stocks could be a huge profit opportunity for marijuana investors. Marijuana-infused products became legal in Canada at the start of 2020, and the industry is expected to experience double-digit growth over the coming years.

Thanks to higher margins, more and more companies are looking to produce cannabis-infused products. If marijuana-derivative products sell well, cannabis extract stocks should rise in value.

Source: https://www.profitconfidential.com/marijuana/cannabis-extraction-stocks-best-profit-play-marijuana-investors/

Tags: , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – #Cannabis Extraction Stocks Best Profit Play for #Marijuana Investors $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Empower Clinics $CBDT.ca Launches Improved Line of #CBD Products and Confirms 2020 Hemp Handlers License for Extraction Facility in Oregon $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:04 AM on Wednesday, February 19th, 2020

Empowers’ CBD product line Sollievo has been reformulated to include 900mg of CBD

  • Launched a series of re-formulated versions of it’s CBD tincture product line SOLLIEVO. Italian for Relief.
  • New formulated Sollievo is non-GMO, non-psychoactive, has rapid bioavailability and is sourced from USA grown hemp.

VANCOUVER BC / February 19, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce it has launched a series of re-formulated versions of it’s CBD tincture product line SOLLIEVO. Italian for Relief.

The new formulated Sollievo is non-GMO, non-psychoactive, has rapid bioavailability and is sourced from USA grown hemp. The products are all third-party lab tested for quality, and the new terpene profiles for each of the four tincture categories of Chronic Pain, Digestion, Insomnia and Anxiety, are aimed to promote mind and body wellness.

“We have spent the last few months dramatically increasing the potency, flavour profiles, and profitability of the Sollievo tincture product lines”, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Our new formulations were manufactured in a state-of-the-art CGMP facility, ensuring quality and consistency, and by tripling the amount of CBD per unit to 900mg, it provides a more potent single dose to our customers, to our patients.”

The new Sollievo tincture lines are now available in the Sun Valley Health wellness clinics, are available online and will be a standard product offering in the Sun Valley Health franchise locations.

The Company also announces it has been awarded its 2020 Oregon Department of Agriculture hemp handlers license, ensuring that the new Sandy, OR extraction and production facility is compliant and licensed to operate under the regulatory framework of the State.

“I’m excited to have our new Sollievo tinctures available for purchase, and so proud of Dustin and our team who have brought an exemplary product to market.” said Steven McAuley, Chairman & CEO of Empower. “Having the hemp handlers license in place for 2020 and continuing toward the close of our Heritage Cannabis joint venture, allows us to control our supply chain and to bring best-in-class CBD products to domestic and international markets.”

The Company also advises that Mat Lee’s position as CFO has concluded and we thank Mat for his contributions. The Company continues to be supported by Invictus Accounting and its team of specialists, who have been integral to creating financial and accounting controls that allow us to report quarterly results well in advance of requirements. The Company has commenced a search for a new Chief Financial Officer.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Launches Improved Line of #CBD Products and Confirms 2020 Hemp Handlers License for Extraction Facility in Oregon $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

INTERVIEW: Empower $CBDT.ca Signs Exclusive Content Deal To Further Convert Its’ Database Of 165,000 Patients $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, February 13th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Add in the fact patient visits increased 351% in Q4 and it becomes the kind of company small cap investors have been dying to find as they watch pretender companies melt away.

But it doesn’t end there.

CBD extraction has been a key element of the company’s vertical integration. Producing its’ own hemp-derived CBD products for its own massive patient list just makes sense. However, thanks to an LOI (moving towards definitive agreement) to JV with extraction experts Heritage Cannabis, the Company’s 5,000 sq ft facility in Oregon is also planning to serve big brand 3rd party partners in the USA .  Empower brings the infrastructure, Heritage brings the expertise and balance sheet.  The result is a match made in shareholder heaven with initial annual capacity of 6,000 Kg at ~ $US 5,000 per Kg, which adds up to $US 30,000,000 in potential revenue.

But It Doesn’t End There

The Company’s CEO, Steven McAuley is Six Sigma certified under the quality initiative of legendary GE chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which also explains how McAuley has brought Empower so far in just 11 months.

If anyone understands digital, it’s McAuley. So it should come as no surprise the Company just signed an exclusive multi-year, multi-national licensing deal with EuroLife to license its “Cannvas.me” cloud based online education platform for the US and Mexico.  Amongst other things, Empower plans to integrate the education platform into its clinics across the United States to help further convert their 165,000 patient database to CBD and medical cannabis through proper education.  

The site also contains premium content for physicians who need to educate themselves and comes with millions of page views already, as well as, 15,000 opted in subscribers, which explains the $460,000 in licensing over 3 years – but $210,000 of that is Empower stock priced at $0.10 (125% above current market prices, which gives you an idea of the confidence EuroLife principals have in the future of Empower.

P.S.  The interview takes place from the floor of the Arizona Cannabis Expo, where Empower has multiple booths and an actual pop-up clinic to acquire new customers in real-time.  That’s what happens when you have a company run by a Six Sigma Certified CEO.

Grab your favourite beverage and settle in to watch what may be your next great small cap investment.

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Empower Clinics Inc., Featured | Comments Off on INTERVIEW: Empower $CBDT.ca Signs Exclusive Content Deal To Further Convert Its’ Database Of 165,000 Patients $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

« Older Entries
Newer Entries »